hydralazine has been researched along with Fatty Liver, Nonalcoholic in 3 studies
Hydralazine: A direct-acting vasodilator that is used as an antihypertensive agent.
hydralazine : The 1-hydrazino derivative of phthalazine; a direct-acting vasodilator that is used as an antihypertensive agent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hypertension is an important risk factor for nonalcoholic steatohepatitis." | 5.56 | The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension. ( Asano, T; Hashimoto, S; Kitamori, K; Naito, H; Nakajima, T; Yuan, Y, 2020) |
| "Hypertension is an important risk factor for nonalcoholic steatohepatitis." | 1.56 | The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension. ( Asano, T; Hashimoto, S; Kitamori, K; Naito, H; Nakajima, T; Yuan, Y, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 2 (66.67) | 2.80 |
| Authors | Studies |
|---|---|
| Yuan, Y | 1 |
| Naito, H | 1 |
| Kitamori, K | 1 |
| Hashimoto, S | 1 |
| Asano, T | 1 |
| Nakajima, T | 1 |
| Yokouchi, C | 1 |
| Nishimura, Y | 1 |
| Goto, H | 1 |
| Sato, M | 1 |
| Hidoh, Y | 1 |
| Takeuchi, K | 1 |
| Ishii, Y | 1 |
| Burgueño, AL | 1 |
| Gianotti, TF | 1 |
| Mansilla, NG | 1 |
| Pirola, CJ | 1 |
| Sookoian, S | 1 |
3 other studies available for hydralazine and Fatty Liver, Nonalcoholic
| Article | Year |
|---|---|
The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension.
Topics: Animals; Antigens, CD; Antigens, Differentiation, Myelomonocytic; Antihypertensive Agents; Blood Pre | 2020 |
Reduction of fatty liver in rats by nicotinamide via the regeneration of the methionine cycle and the inhibition of aldehyde oxidase.
Topics: Administration, Oral; Aldehyde Oxidase; Animals; Disease Models, Animal; Drug Synergism; Drug Therap | 2021 |
Cardiovascular disease is associated with high-fat-diet-induced liver damage and up-regulation of the hepatic expression of hypoxia-inducible factor 1α in a rat model.
Topics: Alanine Transaminase; Analysis of Variance; Animals; Blotting, Western; Cardiovascular Diseases; Die | 2013 |